Gapping down
In reaction to earnings/guidance:
- AVAV -3.5%, BNED -1.5%, BBBY -1.3%, DEA -0.6%, GIS -0.5%
Other news:
- ALT -34.6% (discontinuing further development of AdCOVID beyond completion of Phase 1 trial)
- ANGN -22.1% (announces results from Phase 2 ALI-201 trial of ANG-3777 in patients with severe COVID-19 related pneumonia)
- REPX -16.6% (stock offering)
- CERE -9.1% (stock offering)
- EGLE -7.2% (prices offering of 1,695,182 shares of common stock by selling shareholders at $46.50 per share)
- MDB -6.4% (prices offering of 2.5 mln shares of common stock at $365.00 per share)
- GDYN -3.5% (stock offering)
- PTSI -2.8% (files for $350 mln mixed shelf; also files for 1.5 mln share offering by selling shareholder)
- CDMO -1% (files for mixed securities shelf offering; also files for common stock offering by selling shareholders)
Analyst comments:
- APP -3.2% (double-downgraded to Underweight from Overweight at Morgan Stanley)
- AUDC -2.5% (downgraded to Underweight from Equal Weight at Barclays)
- CDAY -1.7% (downgraded to Underweight from Equal Weight at Barclays)